Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with metastatic non-small cell lung cancer and a MET exon 14 skipping alteration.
LAMPGEN ANALYSIS
Why it matters
Traditional approval confirmed the label for the oral MET inhibitor after expanded follow-up and additional patients in VISION.
What research teams should watch
Verify the exact skipping alteration and track edema, medication interruptions and longitudinal response.
PRIMARY RECORDS